Suppr超能文献

COVID-19 疫苗诱导的过敏反应诊断中的过敏检测及其对疫苗接种的影响。

Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination.

机构信息

Immunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.

UO Direzione Medica di Presidio, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

出版信息

Int Arch Allergy Immunol. 2023;184(1):54-62. doi: 10.1159/000526764. Epub 2022 Oct 20.

Abstract

INTRODUCTION

Immediate and delayed hypersensitivity reactions (HSR) to COVID-19 vaccines are rare adverse events that need to be prevented, diagnosed, and managed in order to guarantee adherence to the vaccination campaign. The aims of our study were to stratify the risk of HSR to COVID-19 vaccines and propose alternative strategies to complete the vaccination.

METHODS

1,640 subjects were screened for vaccinal eligibility, according to national and international recommendations. Among them, we enrolled for allergy workup 152 subjects, 43 with HSR to COVID-19 vaccines and 109 at high risk of HSR to the first dose. In vivo skin tests with drugs and/or vaccines containing PEG/polysorbates were performed in all of them, using skin prick test and, when negative, intradermal tests. In a subgroup of patients resulted negative to the in vivo skin tests, the programmed dose of COVID-19 vaccine (Pfizer/BioNTech) was administered in graded doses regimen, and detection of neutralizing anti-spike antibodies was performed in these patients after 4 weeks from the vaccination, using the SPIA method.

RESULTS

Skin tests for PEG/polysorbates resulted positive in only 3% (5/152) of patients, including 2 with previous HSR to COVID-19 vaccines and 3 at high risk of HSR to the first dose. Among the 147 patients with negative skin tests, 97% (143/147) were eligible for vaccination and 87% (124/143) of them received safely the programmed COVID-19 vaccine dose. Administration of graded doses of Pfizer/BioNTech vaccine were well tolerated in 17 out of 18 patients evaluated; only 1 developed an HSR during the vaccination, less severe than the previous one, and all developed neutralizing anti-spike antibodies after 4 weeks with values comparable to those subjects who received the vaccine in unfractionated dose.

CONCLUSION

On the whole, the usefulness of the skin tests for PEG/polysorbates seems limited in the diagnosis of HSR to COVID-19 vaccines. Graded doses regimen (Pfizer/BioNTech) is a safe and effective alternative strategy to complete the vaccinal course.

摘要

简介

对 COVID-19 疫苗的即刻和迟发性超敏反应 (HSR) 是罕见的不良事件,需要加以预防、诊断和处理,以确保疫苗接种的依从性。我们研究的目的是对 COVID-19 疫苗的 HSR 风险进行分层,并提出完成疫苗接种的替代策略。

方法

根据国家和国际建议,对 1640 名受试者进行了疫苗接种资格筛查。其中,我们对 152 名有过敏史的受试者进行了过敏工作评估,其中 43 名对 COVID-19 疫苗有 HSR,109 名对第一剂疫苗有 HSR 高风险。对所有受试者进行了含有 PEG/聚山梨酯的药物和/或疫苗的体内皮肤试验,包括皮肤点刺试验和阴性时的皮内试验。在一组体内皮肤试验阴性的患者中,给予了程序剂量的 COVID-19 疫苗(辉瑞/生物科技),并在接种后 4 周,采用 SPIA 法检测这些患者的中和抗刺突抗体。

结果

仅 3%(5/152)的患者对 PEG/聚山梨酯的皮肤试验呈阳性,包括 2 例对 COVID-19 疫苗有 HSR,3 例对第一剂疫苗有 HSR 高风险。在 147 例皮肤试验阴性的患者中,97%(143/147)有资格接种疫苗,其中 87%(124/143)安全接种了程序剂量的 COVID-19 疫苗。在接受评估的 18 名患者中,有 17 名患者对辉瑞/生物科技的分级剂量疫苗耐受良好;只有 1 名患者在接种疫苗期间发生了 HSR,比以前的症状轻,所有患者在接种后 4 周均产生了中和抗刺突抗体,其值与接种全剂量疫苗的患者相当。

结论

总的来说,PEG/聚山梨酯皮肤试验对 COVID-19 疫苗的 HSR 诊断似乎作用有限。分级剂量方案(辉瑞/生物科技)是一种安全有效的替代策略,可用于完成疫苗接种疗程。

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验